Company Login
Site Newsletter
Welcome to PharmiWeb.com
Latest Press Releases
- SCHERING-PLOUGH ANNOUNCES PHASE II AND III DATA FOR CORIFOLLITROPIN ALFA
02 Jul 09
Fleishman-Hillard - Novartis receives Complete Response letter from the US Food and Drug Administration for its investigational vaccine Menveo®
02 Jul 09
PharmiWeb.com - Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer
02 Jul 09
PharmiWeb.com - Roche launches novel program to ease Tamiflu access to developing economies
02 Jul 09
PharmiWeb - SCHERING-PLOUGH ANNOUNCES PHASE II AND III DATA FOR CORIFOLLITROPIN ALFA
01 Jul 09
Pharmiweb.com
Latest News
FDA Tells Patients to Stick With Diabetes Drug Linked to CancerMedicineNet.com
02 Jul 09 , 23:15
FDA Warning on Stop-Smoking DrugsMedicineNet.com
02 Jul 09 , 23:14
Black Box Warnings Required on Quit-Smoking DrugsFDA News
02 Jul 09 , 23:10
Drug Discovery Unit, University of Dundee, and DNDi Collaborate to Identify Drug Candidates to Treat Visceral LeishmaniasisCombiChemnet
02 Jul 09 , 23:07
J&J buys $1 billion Elan stake, gains Alzheimer's R&DGlobe Investor
02 Jul 09 , 23:02
Latest Events
- Clinical Oncology
06 Jul 09 - 10 Jul 09 - THE MEDICAL DEVICE SUMMER SCHOOL - 5 Day Residential Course - London - From Concept to CE Marking
06 Jul 09 - 10 Jul 09 - INTRODUCTORY OVERVIEW OF THE PHARMA INDUSTRY
06 Jul 09 - 06 Jul 09
pharmiweb.com today | 03 July 2009
Sanofi-aventis's New R&D Model
Sanofi-aventis has presented a new R&D Model Project aimed to boost innovation is the first pillar of the Group’s new strategy which was presented in February 2009 by Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis.
“The objective of this new R&D model is to propose innovative solutions that respond to specific, unmet needs of patients and continue our success in a very competitive international environment,” declared Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis. “It is centered on the real needs of patients, the development of scientific networks and openness toward outside entities to strengthen creativity, and a flexible and entrepreneurial approach to research.”
The company claimed "The rapid evolution of the scientific environment, which is bringing about a veritable revolution in biopharmaceutical research, namely in biology, has generated a profound and continuous change in the pharmaceutical environment. To anticipate the consequences of this mutation and to maintain its innovative capacities, sanofi-aventis intends to set in place the most effective R&D organization in the pharmaceutical industry by 2013."
Latest Features
Networking as a tool to help you find your next job in Clinical Research
02 Jul 09
Getting a job in Clinical research or Regulatory Affairs can be tough at the best of times.
World Vaccine Congress Asia: vast regional diversity requires flexibility and targeted portfolios
01 Jul 09
Spanning one third of the globe's circumference and home to more than half of the world's population, the Asia Pacific region is incredibly diverse.
The 10th Annual Congress of the European League Against Rheumatism (EULAR)
18 Jun 09
Field reporter Rhonda Siddall reports from EULAR
Latest Poll
